10x Genomics, Inc.
For the period ended Jun 4, 2026. Filed Apr 24, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 4, 2026 · Filed Apr 24, 2026
Contents
PAY-VERSUS-PERFORMANCE
Pay Versus Performance Disclosure
In accordance with rules adopted by the Securities and Exchange Commission pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we provide the following disclosure regarding executive compensation for our principal executive officer (“PEO”) and Non-PEO NEOs and Company performance for the fiscal years listed below.
| Year · Summary Compensation Table Total for PEO1 ($) · Compensation Actually Paid to PEO1,2,3 ($) · Average Summary Compensation Table Total for Non-PEO NEOs1 ($) · Average Compensation Actually Paid to Non-PEO NEOs1,2,3 ($) · Value of Initial Fixed $100 Investment based on:4 · Net Income($ Millions) · Stock Price⁵ | ||||||||
|---|---|---|---|---|---|---|---|---|
| TSR ($) · Peer Group TSR ($) | ||||||||
| 2025 | 6,329,244 | 6,788,069 | 2,759,812 | 3,670,771 | 11.52 | 124.75 | (43.5) | 16.31 |
| 2024 | 7,929,349 | (21,169,246) | 4,399,950 | (4,682,313) | 10.14 | 93.49 | (182.6) | 14.36 |
| 2023 | 8,286,049 | 17,348,412 | 3,397,530 | 7,387,885 | 39.52 | 94.03 | (255.1) | 55.96 |
| 2022 | 18,805,294 | (14,310,774) | 9,376,988 | (3,497,039) | 25.73 | 89.90 | (166.0) | 36.44 |
| 2021 | 11,700,985 | 20,812,842 | 4,979,234 | 9,325,452 | 105.20 | 100.02 | (58.2) | 148.96 |
(1)Serge Saxonov was our PEO for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below.
| 2021 | 2022 | 2023 | 2024 | 2025 |
| Justin J. McAnear | Justin J. McAnear | Justin J. McAnear | Adam S. Taich | Adam S. Taich |
| Benjamin J. Hindson | Benjamin J. Hindson | Benjamin J. Hindson | Benjamin J. Hindson | Benjamin J. Hindson |
| Eric S. Whitaker | Eric S. Whitaker | Eric S. Whitaker | Eric S. Whitaker | Eric S. Whitaker |
| Bradford J. Crutchfield | James Wilbur | James Wilbur | Justin J. McAnear |
(2)The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized or received by the Company’s Non-PEO NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below.
| 10X GENOMICS, INC. | 61 | 2026 PROXY STATEMENT |
|---|
(3)Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table.
| Year | Summary Compensation Table Total forSerge Saxonov ($) | Exclusion of Stock Awards and Option Awardsfor Serge Saxonov ($) | Inclusion ofEquity Values forSerge Saxonov ($) | Compensation ActuallyPaid to Serge Saxonov ($) |
|---|---|---|---|---|
| 2025 | 6,329,244 | (5,020,269) | 5,479,094 | 6,788,069 |
| Year | Average Summary Compensation TableTotal for Non-PEO NEOs ($) | Average Exclusion of Stock Awards and Option Awards forNon-PEO NEOs($) | Average Inclusionof Equity Values forNon-PEO NEOs ($) | Average Compensation Actually Paid toNon-PEO NEOs ($) |
|---|---|---|---|---|
| 2025 | 2,759,812 | (1,954,729) | 2,865,688 | 3,670,771 |
The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
| Year | Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Serge Saxonov ($) | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Serge Saxonov ($) | Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Serge Saxonov ($) | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Serge Saxonov ($) | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Serge Saxonov ($) | Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Serge Saxonov ($) | Total - Inclusion of EquityValues forSerge Saxonov ($) |
|---|---|---|---|---|---|---|---|
| 2025 | 5,290,273 | (212,419) | 568,003 | (166,763) | — | — | 5,479,094 |
| Year | Average Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non-PEO NEOs ($) | Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs ($) | Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Non-PEO NEOs ($) | Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non-PEO NEOs ($) | Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs ($) | Average Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Non-PEO NEOs ($) | Total - Average Inclusion ofEquity Values for Non-PEO NEOs($) |
|---|---|---|---|---|---|---|---|
| 2025 | 2,353,457 | 147,538 | 476,288 | (111,595) | — | — | 2,865,688 |
(4)The Peer Group TSR set forth in this table utilizes the Nasdaq Biotechnology Composite Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the year ended December 31, 2025. The comparison assumes $100 was invested for the period starting December 31, 2020, through the end of the listed year in the Company and in the Nasdaq Biotechnology Composite Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.
(5)We determined stock price to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and Non-PEO NEOs in 2025. The amounts in the column represent the closing price on the last trading day of the listed year.
| 10X GENOMICS, INC. | 62 | 2026 PROXY STATEMENT |
|---|
Relationship Between PEO and Non-PEO NEO Compensation Actually Paid, Company Total Shareholder Return (“TSR”) and Cumulative TSR Comparison
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs and the Company’s cumulative TSR over the five most recently completed fiscal years. The chart also compares the Company’s TSR to that of the Nasdaq Biotechnology Composite Index over the same period.
| 10X GENOMICS, INC. | 63 | 2026 PROXY STATEMENT |
|---|
Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Income
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs and our Net Income during the five most recently completed fiscal years.
Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Stock Price
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Stock Price during the five most recently completed fiscal years.
| 10X GENOMICS, INC. | 64 | 2026 PROXY STATEMENT |
|---|
Tabular List of Most Important Financial Performance Measures
The following table presents the financial performance measures the Company considers to have been the most important in linking Compensation Actually Paid to our PEO and other NEOs for 2025 to Company performance. We used stock price hurdles as the vesting condition for performance-based equity awards in 2022 and 2023, relative TSR as the vesting condition for performance-based equity awards in 2024 and 2025, and funding of our 2024 and 2025 Annual Incentive Plan was based on annual revenue achievement. The measures in this table are not ranked.
Stock Price
Relative TSR
Revenue
| 10X GENOMICS, INC. | 65 | 2026 PROXY STATEMENT |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.